25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Seoulin Bioscience Co.Ltd
Buy, Hold or Sell?

Let's analyze Seoulin together

I guess you are interested in Seoulin Bioscience Co.Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Seoulin Bioscience Co.Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Seoulin Bioscience Co.Ltd

I send you an email if I find something interesting about Seoulin Bioscience Co.Ltd.

1. Quick Overview

1.1. Quick analysis of Seoulin (30 sec.)










1.2. What can you expect buying and holding a share of Seoulin? (30 sec.)

How much money do you get?

How much money do you get?
₩0.09
When do you have the money?
1 year
How often do you get paid?
80.0%

What is your share worth?

Current worth
₩10,006.61
Expected worth in 1 year
₩9,993.76
How sure are you?
90.0%

+ What do you gain per year?

Total Gains per Share
₩113.10
Return On Investment
1.5%

For what price can you sell your share?

Current Price per Share
₩7,790.00
Expected price per share
₩6,130 - ₩10,892
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Seoulin (5 min.)




Live pricePrice per Share (EOD)
₩7,790.00

2.2. Growth of Seoulin (5 min.)




Is Seoulin growing?

Current yearPrevious yearGrowGrow %
How rich?$59.9m$58.9m$739.9k1.2%

How much money is Seoulin making?

Current yearPrevious yearGrowGrow %
Making money-$103.3k$582.4k-$685.7k-663.5%
Net Profit Margin0.1%3.8%--

How much money comes from the company's main activities?

2.3. Financial Health of Seoulin (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Seoulin?

Welcome investor! Seoulin's management wants to use your money to grow the business. In return you get a share of Seoulin.

First you should know what it really means to hold a share of Seoulin. And how you can make/lose money.

Speculation

The Price per Share of Seoulin is ₩7,790. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Seoulin.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Seoulin, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩10,006.61. Based on the TTM, the Book Value Change Per Share is ₩-3.21 per quarter. Based on the YOY, the Book Value Change Per Share is ₩62.81 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩31.49 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Seoulin.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.070.0%-0.010.0%0.070.0%0.140.0%0.110.0%
Usd Book Value Change Per Share0.050.0%0.000.0%0.040.0%0.100.0%0.090.0%
Usd Dividend Per Share0.000.0%0.020.0%0.060.0%0.050.0%0.050.0%
Usd Total Gains Per Share0.050.0%0.020.0%0.100.0%0.150.0%0.130.0%
Usd Price Per Share5.86-6.39-8.20-9.20-9.14-
Price to Earnings Ratio21.71-21.34-134.83-37.31-44.28-
Price-to-Total Gains Ratio115.52-146.59-99.66-158.54-130.66-
Price to Book Ratio0.84-0.91-1.17-1.55-1.89-
Price-to-Total Gains Ratio115.52-146.59-99.66-158.54-130.66-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share5.453
Number of shares183
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.020.05
Usd Book Value Change Per Share0.000.10
Usd Total Gains Per Share0.020.15
Gains per Quarter (183 shares)3.6228.01
Gains per Year (183 shares)14.49112.04
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
116-243874102
232-31876148214
348-532115221326
465-746153295438
581-860191369550
697-1074229443662
7113-1288268517774
8129-13102306590886
9145-15116344664998
10161-161303827381110

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.01.00.075.0%10.02.00.083.3%18.02.00.090.0%37.02.01.092.5%39.02.01.092.9%
Book Value Change Per Share3.01.00.075.0%9.03.00.075.0%15.05.00.075.0%31.09.00.077.5%33.09.00.078.6%
Dividend per Share1.00.03.025.0%7.00.05.058.3%15.00.05.075.0%32.00.08.080.0%33.00.09.078.6%
Total Gains per Share3.01.00.075.0%11.01.00.091.7%18.02.00.090.0%36.04.00.090.0%38.04.00.090.5%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Seoulin Bioscience Co.Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--72.454-3.213+104%62.813+15%144.036-50%124.132-42%
Book Value Per Share--10006.61210032.5290%9975.806+0%8704.545+15%7301.742+37%
Current Ratio--3.9233.008+30%1.915+105%2.810+40%1.994+97%
Debt To Asset Ratio--0.1670.246-32%0.391-57%0.300-44%0.283-41%
Debt To Equity Ratio--0.2060.351-41%0.643-68%0.455-55%0.414-50%
Dividend Per Share---31.487-100%78.813-100%74.618-100%68.245-100%
Enterprise Value--54379539210.00061567503073.437-12%102842792366.640-47%110666645823.366-51%101100606953.950-46%
Eps--96.378-18.062+119%98.632-2%197.044-51%153.769-37%
Ev To Ebitda Ratio--infinfnan%infnan%infnan%infnan%
Ev To Sales Ratio--0.6870.753-9%1.226-44%1.394-51%1.740-61%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.975+3%
Market Cap65716284200.000-9%71580516210.00077483222165.937-8%98764134829.140-28%110936995296.865-35%110184206078.700-35%
Net Profit Margin--0.0420.001+4476%0.038+10%0.078-47%0.078-47%
Operating Margin----0%-0%0.032-100%0.022-100%
Operating Ratio--1.4911.692-12%1.427+4%1.169+28%1.156+29%
Pb Ratio0.778-7%0.8360.909-8%1.174-29%1.547-46%1.889-56%
Pe Ratio20.207-7%21.71121.337+2%134.828-84%37.313-42%44.278-51%
Price Per Share7790.000-7%8370.0009122.498-8%11707.488-29%13137.987-36%13054.987-36%
Price To Free Cash Flow Ratio---19.615-100%-10.3100%60.434-100%22.456-100%
Price To Total Gains Ratio107.517-7%115.522146.586-21%99.664+16%158.543-27%130.664-12%
Quick Ratio---1.169-100%2.319-100%2.576-100%1.817-100%
Return On Assets--0.008-0.001+115%0.006+35%0.017-52%0.015-47%
Return On Equity--0.010-0.002+119%0.0100%0.023-57%0.021-52%
Total Gains Per Share--72.45428.274+156%141.627-49%218.654-67%192.377-62%
Usd Book Value--59903813.20059648934.909+0%58908990.287+2%51482951.291+16%43158643.161+39%
Usd Book Value Change Per Share--0.051-0.002+104%0.044+15%0.101-50%0.087-42%
Usd Book Value Per Share--7.0057.0230%6.983+0%6.093+15%5.111+37%
Usd Dividend Per Share---0.022-100%0.055-100%0.052-100%0.048-100%
Usd Enterprise Value--38065677.44743097252.151-12%71989954.657-47%77466652.076-51%70770424.868-46%
Usd Eps--0.067-0.013+119%0.069-2%0.138-51%0.108-37%
Usd Free Cash Flow---924654.010-100%-1760089.7720%202700.559-100%-191134.9830%
Usd Market Cap46001398.940-9%50106361.34754238255.516-8%69134894.380-28%77655896.708-35%77128944.255-35%
Usd Price Per Share5.453-7%5.8596.386-8%8.195-29%9.197-36%9.138-36%
Usd Profit--576961.000-103359.139+118%582438.983-1%1164239.200-50%908364.648-36%
Usd Revenue--13855832.90014789960.754-6%14741219.192-6%14208878.189-2%11012392.458+26%
Usd Total Gains Per Share--0.0510.020+156%0.099-49%0.153-67%0.135-62%
 EOD+3 -4MRQTTM+18 -15YOY+14 -175Y+10 -2410Y+12 -22

3.3 Fundamental Score

Let's check the fundamental score of Seoulin Bioscience Co.Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1520.207
Price to Book Ratio (EOD)Between0-10.778
Net Profit Margin (MRQ)Greater than00.042
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than13.923
Debt to Asset Ratio (MRQ)Less than10.167
Debt to Equity Ratio (MRQ)Less than10.206
Return on Equity (MRQ)Greater than0.150.010
Return on Assets (MRQ)Greater than0.050.008
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Seoulin Bioscience Co.Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.379
Ma 20Greater thanMa 507,379.500
Ma 50Greater thanMa 1007,187.800
Ma 100Greater thanMa 2007,609.000
OpenGreater thanClose7,640.000
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Seoulin Bioscience Co.Ltd

Seoulin Bioscience Co.,Ltd., a bio healthcare company, provides solutions in life sciences and healthcare primarily in South Korea. The company offers solutions for bio research and production; ecoTree, a SLB-120 instrument which produces slightly acidic electrolyzed water for used in food industry, living, and laboratory; plasma-based medical esthetics; miQ for the diagnosis of dementia; and functional cosmetics based on natural fermentation. Seoulin Bioscience Co.,Ltd. was founded in 1984 and is headquartered in Seongnam-si, South Korea.

Fundamental data was last updated by Penke on 2024-12-09 15:35:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is not making a profit/loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is underpriced.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Seoulin earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare Seoulin to the Biotechnology industry mean.
  • A Net Profit Margin of 4.2% means that ₩0.04 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Seoulin Bioscience Co.Ltd:

  • The MRQ is 4.2%. The company is making a profit. +1
  • The TTM is 0.1%. The company is not making a profit/loss.
Trends
Current periodCompared to+/- 
MRQ4.2%TTM0.1%+4.1%
TTM0.1%YOY3.8%-3.7%
TTM0.1%5Y7.8%-7.7%
5Y7.8%10Y7.8%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.2%-108.6%+112.8%
TTM0.1%-220.8%+220.9%
YOY3.8%-207.5%+211.3%
5Y7.8%-350.0%+357.8%
10Y7.8%-473.2%+481.0%
4.3.1.2. Return on Assets

Shows how efficient Seoulin is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Seoulin to the Biotechnology industry mean.
  • 0.8% Return on Assets means that Seoulin generated ₩0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Seoulin Bioscience Co.Ltd:

  • The MRQ is 0.8%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is -0.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ0.8%TTM-0.1%+0.9%
TTM-0.1%YOY0.6%-0.7%
TTM-0.1%5Y1.7%-1.8%
5Y1.7%10Y1.5%+0.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8%-11.6%+12.4%
TTM-0.1%-11.9%+11.8%
YOY0.6%-11.2%+11.8%
5Y1.7%-12.6%+14.3%
10Y1.5%-14.2%+15.7%
4.3.1.3. Return on Equity

Shows how efficient Seoulin is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Seoulin to the Biotechnology industry mean.
  • 1.0% Return on Equity means Seoulin generated ₩0.01 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Seoulin Bioscience Co.Ltd:

  • The MRQ is 1.0%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is -0.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ1.0%TTM-0.2%+1.2%
TTM-0.2%YOY1.0%-1.2%
TTM-0.2%5Y2.3%-2.5%
5Y2.3%10Y2.1%+0.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0%-14.3%+15.3%
TTM-0.2%-15.9%+15.7%
YOY1.0%-14.7%+15.7%
5Y2.3%-18.5%+20.8%
10Y2.1%-19.2%+21.3%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Seoulin Bioscience Co.Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Seoulin is operating .

  • Measures how much profit Seoulin makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Seoulin to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Seoulin Bioscience Co.Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y3.2%-3.2%
5Y3.2%10Y2.2%+1.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--204.0%+204.0%
TTM--316.3%+316.3%
YOY--216.2%+216.2%
5Y3.2%-379.8%+383.0%
10Y2.2%-480.9%+483.1%
4.3.2.2. Operating Ratio

Measures how efficient Seoulin is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.49 means that the operating costs are ₩1.49 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of Seoulin Bioscience Co.Ltd:

  • The MRQ is 1.491. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.692. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.491TTM1.692-0.201
TTM1.692YOY1.427+0.265
TTM1.6925Y1.169+0.524
5Y1.16910Y1.156+0.012
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4912.284-0.793
TTM1.6923.244-1.552
YOY1.4273.247-1.820
5Y1.1694.764-3.595
10Y1.1566.437-5.281
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Seoulin Bioscience Co.Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Seoulin is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.92 means the company has ₩3.92 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of Seoulin Bioscience Co.Ltd:

  • The MRQ is 3.923. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.008. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.923TTM3.008+0.916
TTM3.008YOY1.915+1.093
TTM3.0085Y2.810+0.198
5Y2.81010Y1.994+0.816
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.9233.586+0.337
TTM3.0083.865-0.857
YOY1.9154.644-2.729
5Y2.8105.968-3.158
10Y1.9946.215-4.221
4.4.3.2. Quick Ratio

Measures if Seoulin is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Seoulin to the Biotechnology industry mean.
  • A Quick Ratio of 0.00 means the company can pay off ₩0.00 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Seoulin Bioscience Co.Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM1.169-1.169
TTM1.169YOY2.319-1.150
TTM1.1695Y2.576-1.407
5Y2.57610Y1.817+0.759
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.099-3.099
TTM1.1693.384-2.215
YOY2.3194.304-1.985
5Y2.5765.954-3.378
10Y1.8176.436-4.619
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Seoulin Bioscience Co.Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Seoulin assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Seoulin to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.17 means that Seoulin assets are financed with 16.7% credit (debt) and the remaining percentage (100% - 16.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Seoulin Bioscience Co.Ltd:

  • The MRQ is 0.167. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.246. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.167TTM0.246-0.079
TTM0.246YOY0.391-0.145
TTM0.2465Y0.300-0.054
5Y0.30010Y0.283+0.017
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1670.346-0.179
TTM0.2460.346-0.100
YOY0.3910.314+0.077
5Y0.3000.365-0.065
10Y0.2830.383-0.100
4.5.4.2. Debt to Equity Ratio

Measures if Seoulin is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Seoulin to the Biotechnology industry mean.
  • A Debt to Equity ratio of 20.6% means that company has ₩0.21 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Seoulin Bioscience Co.Ltd:

  • The MRQ is 0.206. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.351. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.206TTM0.351-0.145
TTM0.351YOY0.643-0.292
TTM0.3515Y0.455-0.104
5Y0.45510Y0.414+0.042
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2060.393-0.187
TTM0.3510.432-0.081
YOY0.6430.390+0.253
5Y0.4550.452+0.003
10Y0.4140.498-0.084
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings Seoulin generates.

  • Above 15 is considered overpriced but always compare Seoulin to the Biotechnology industry mean.
  • A PE ratio of 21.71 means the investor is paying ₩21.71 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Seoulin Bioscience Co.Ltd:

  • The EOD is 20.207. Based on the earnings, the company is fair priced.
  • The MRQ is 21.711. Based on the earnings, the company is fair priced.
  • The TTM is 21.337. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD20.207MRQ21.711-1.504
MRQ21.711TTM21.337+0.375
TTM21.337YOY134.828-113.492
TTM21.3375Y37.313-15.976
5Y37.31310Y44.278-6.965
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD20.207-2.123+22.330
MRQ21.711-2.548+24.259
TTM21.337-3.161+24.498
YOY134.828-3.244+138.072
5Y37.313-6.006+43.319
10Y44.278-6.717+50.995
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Seoulin Bioscience Co.Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM19.615-19.615
TTM19.615YOY-10.310+29.925
TTM19.6155Y60.434-40.819
5Y60.43410Y22.456+37.978
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--3.295+3.295
TTM19.615-3.674+23.289
YOY-10.310-4.477-5.833
5Y60.434-8.046+68.480
10Y22.456-9.204+31.660
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Seoulin is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.84 means the investor is paying ₩0.84 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of Seoulin Bioscience Co.Ltd:

  • The EOD is 0.778. Based on the equity, the company is cheap. +2
  • The MRQ is 0.836. Based on the equity, the company is cheap. +2
  • The TTM is 0.909. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.778MRQ0.836-0.058
MRQ0.836TTM0.909-0.073
TTM0.909YOY1.174-0.264
TTM0.9095Y1.547-0.638
5Y1.54710Y1.889-0.342
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.7781.919-1.141
MRQ0.8362.055-1.219
TTM0.9092.389-1.480
YOY1.1742.454-1.280
5Y1.5473.716-2.169
10Y1.8894.373-2.484
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in KRW. All numbers in thousands.

Summary
Total Assets102,777,853
Total Liabilities17,200,977
Total Stockholder Equity83,577,470
 As reported
Total Liabilities 17,200,977
Total Stockholder Equity+ 83,577,470
Total Assets = 102,777,853

Assets

Total Assets102,777,853
Total Current Assets62,514,448
Long-term Assets40,263,404
Total Current Assets
Total Current Assets  (as reported)62,514,448
Total Current Assets  (calculated)0
+/- 62,514,448
Long-term Assets
Long-term Assets  (as reported)40,263,404
Long-term Assets  (calculated)0
+/- 40,263,404

Liabilities & Shareholders' Equity

Total Current Liabilities15,934,350
Long-term Liabilities1,266,627
Total Stockholder Equity83,577,470
Total Current Liabilities
Total Current Liabilities  (as reported)15,934,350
Total Current Liabilities  (calculated)0
+/- 15,934,350
Long-term Liabilities
Long-term Liabilities  (as reported)1,266,627
Long-term Liabilities  (calculated)0
+/- 1,266,627
Total Stockholder Equity
Total Stockholder Equity (as reported)83,577,470
Total Stockholder Equity (calculated)0
+/- 83,577,470
Other
Common Stock Shares Outstanding 8,552
Net Invested Capital 83,577,470
Net Working Capital 46,580,098



6.2. Balance Sheets Structured

Currency in KRW. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-31
> Total Assets 
59,853,799
58,551,835
59,483,280
60,718,451
63,827,286
64,151,814
66,119,670
66,103,985
60,665,764
63,435,287
65,953,749
66,469,926
69,307,208
73,155,288
72,935,597
71,038,280
70,905,421
71,218,169
71,599,993
71,611,770
70,065,728
74,437,025
75,738,566
80,707,446
76,894,774
79,029,930
80,446,590
78,246,746
79,906,856
87,208,545
98,554,061
136,566,038
138,833,683
135,421,137
139,273,718
134,868,765
141,565,198
137,257,963
138,408,850
114,099,910
103,497,214
102,777,853
102,777,853103,497,214114,099,910138,408,850137,257,963141,565,198134,868,765139,273,718135,421,137138,833,683136,566,03898,554,06187,208,54579,906,85678,246,74680,446,59079,029,93076,894,77480,707,44675,738,56674,437,02570,065,72871,611,77071,599,99371,218,16970,905,42171,038,28072,935,59773,155,28869,307,20866,469,92665,953,74963,435,28760,665,76466,103,98566,119,67064,151,81463,827,28660,718,45159,483,28058,551,83559,853,799
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
34,999,812
33,873,123
31,949,572
32,094,063
31,991,530
32,972,036
32,770,378
31,680,505
37,960,959
39,068,191
43,803,199
40,155,769
42,538,193
39,505,539
41,461,745
43,300,986
48,854,188
66,509,308
100,846,436
106,870,671
101,134,545
102,107,749
86,669,372
101,159,960
93,575,774
94,135,171
72,954,684
62,572,870
62,514,448
62,514,44862,572,87072,954,68494,135,17193,575,774101,159,96086,669,372102,107,749101,134,545106,870,671100,846,43666,509,30848,854,18843,300,98641,461,74539,505,53942,538,19340,155,76943,803,19939,068,19137,960,95931,680,50532,770,37832,972,03631,991,53032,094,06331,949,57233,873,12334,999,8120000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
3,360,269
929,171
3,419,613
1,567,604
1,898,883
3,013,052
3,805,346
2,154,173
2,975,027
3,472,166
4,539,854
2,577,174
1,934,749
3,563,451
8,494,191
8,839,126
9,772,884
10,637,478
160
4,933
5,183
5,532
3,257
2,456
3,056
1,763
14,601,833
13,745,918
0
013,745,91814,601,8331,7633,0562,4563,2575,5325,1834,93316010,637,4789,772,8848,839,1268,494,1913,563,4511,934,7492,577,1744,539,8543,472,1662,975,0272,154,1733,805,3463,013,0521,898,8831,567,6043,419,613929,1713,360,2690000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,721,000
7,341,000
6,791,000
6,217,764
7,175,420
5,925,420
6,172,041
15,295,760
16,921,934
17,497,304
0
0
11,366,260
10,361,530
10,958,911
10,580,989
29,031,355
58,308,990
56,297,672
55,221,187
54,671,865
43,794,722
51,376,929
43,282,594
40,550,291
20,812,366
17,228,024
0
017,228,02420,812,36640,550,29143,282,59451,376,92943,794,72254,671,86555,221,18756,297,67258,308,99029,031,35510,580,98910,958,91110,361,53011,366,2600017,497,30416,921,93415,295,7606,172,0415,925,4207,175,4206,217,7646,791,0007,341,00010,721,00000000000000000
       Net Receivables 
10,985,032
11,872,420
11,660,893
12,987,916
12,282,697
11,934,425
10,607,376
10,661,940
10,519,630
12,776,919
12,110,081
9,490,396
11,634,696
9,579,592
8,840,223
7,214,511
8,575,894
8,784,976
7,586,037
6,819,574
7,769,953
6,968,064
7,519,092
8,399,401
8,760,941
8,411,602
9,670,656
8,908,187
11,178,444
13,662,884
13,409,017
10,286,597
17,610,511
18,950,421
12,812,025
7,210,207
8,850,384
10,834,568
7,627,717
12,985,711
6,583,891
0
06,583,89112,985,7117,627,71710,834,5688,850,3847,210,20712,812,02518,950,42117,610,51110,286,59713,409,01713,662,88411,178,4448,908,1879,670,6568,411,6028,760,9418,399,4017,519,0926,968,0647,769,9536,819,5747,586,0378,784,9768,575,8947,214,5118,840,2239,579,59211,634,6969,490,39612,110,08112,776,91910,519,63010,661,94010,607,37611,934,42512,282,69712,987,91611,660,89311,872,42010,985,032
       Other Current Assets 
403,602
436,268
439,176
607,560
20,373,129
454,491
783,687
20,496,938
541,934
371,930
361,714
329,999
451,198
278,503
335,140
634,016
728,840
293,566
277,500
1,073,876
1,543,130
1,151,797
700,000
1,306,940
2,608,807
4,950,015
985,694
924,780
378,934
608,762
1,215,528
2,050,000
6,216,160
4,313,558
4,265,222
4,952,585
5,054,825
4,542,101
4,542,101
0
-1
0
0-104,542,1014,542,1015,054,8254,952,5854,265,2224,313,5586,216,1602,050,0001,215,528608,762378,934924,780985,6944,950,0152,608,8071,306,940700,0001,151,7971,543,1301,073,876277,500293,566728,840634,016335,140278,503451,198329,999361,714371,930541,93420,496,938783,687454,49120,373,129607,560439,176436,268403,602
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
48,199,392
40,405,238
43,682,189
44,273,679
41,145,226
40,924,344
40,263,404
40,263,40440,924,34441,145,22644,273,67943,682,18940,405,23848,199,39200000000000000000000000000000000000
       Property Plant Equipment 
13,208,627
13,085,535
13,277,798
13,225,130
15,958,277
15,851,285
15,885,218
15,980,547
17,273,756
17,319,399
18,911,077
20,022,717
24,614,818
27,330,730
28,028,309
27,243,317
27,030,160
26,982,165
26,674,054
26,615,617
26,433,018
26,290,188
26,052,063
25,919,990
25,721,683
25,470,006
25,404,891
14,540,757
14,773,631
15,185,537
15,240,684
14,936,518
14,804,636
14,723,437
15,807,155
16,491,101
16,825,410
19,046,410
19,203,009
18,913,976
18,648,927
0
018,648,92718,913,97619,203,00919,046,41016,825,41016,491,10115,807,15514,723,43714,804,63614,936,51815,240,68415,185,53714,773,63114,540,75725,404,89125,470,00625,721,68325,919,99026,052,06326,290,18826,433,01826,615,61726,674,05426,982,16527,030,16027,243,31728,028,30927,330,73024,614,81820,022,71718,911,07717,319,39917,273,75615,980,54715,885,21815,851,28515,958,27713,225,13013,277,79813,085,53513,208,627
       Goodwill 
526,485
526,485
526,485
526,485
526,485
526,485
526,485
1,166,012
1,716,012
1,166,012
1,166,012
1,166,012
1,166,012
1,166,012
1,166,012
1,166,012
1,166,012
1,166,012
1,166,012
1,166,012
1,166,012
526,486
526,486
526,486
526,486
526,486
526,486
526,486
526,486
526,486
526,486
526,486
526,486
526,486
526,486
526,486
526,486
526,486
526,486
526,486
526,486
0
0526,486526,486526,486526,486526,486526,486526,486526,486526,486526,486526,486526,486526,486526,486526,486526,486526,486526,486526,486526,4861,166,0121,166,0121,166,0121,166,0121,166,0121,166,0121,166,0121,166,0121,166,0121,166,0121,166,0121,166,0121,716,0121,166,012526,485526,485526,485526,485526,485526,485526,485
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
5,537,071
5,549,596
6,146,696
6,143,007
6,205,425
6,272,178
6,619,070
6,654,114
5,976,470
6,018,423
6,084,045
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000006,084,0456,018,4235,976,4706,654,1146,619,0706,272,1786,205,4256,143,0076,146,6965,549,5965,537,0710000000000000
       Intangible Assets 
1,213,922
1,203,196
1,199,234
1,370,947
1,367,818
1,345,573
1,339,833
1,966,150
2,511,251
1,944,019
1,926,561
1,915,338
1,915,940
1,899,847
1,883,753
1,753,814
1,742,204
797,709
784,762
761,356
732,579
423,004
2,301,164
2,285,014
2,361,074
2,232,921
2,156,495
2,034,542
1,883,821
1,790,970
1,689,058
788,549
756,516
769,749
803,233
477,606
440,228
417,915
358,005
581,161
564,274
0
0564,274581,161358,005417,915440,228477,606803,233769,749756,516788,5491,689,0581,790,9701,883,8212,034,5422,156,4952,232,9212,361,0742,285,0142,301,164423,004732,579761,356784,762797,7091,742,2041,753,8141,883,7531,899,8471,915,9401,915,3381,926,5611,944,0192,511,2511,966,1501,339,8331,345,5731,367,8181,370,9471,199,2341,203,1961,213,922
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
1
0
0
-1
0
0-10010100000000000000000000000000000000000
> Total Liabilities 
17,997,876
16,023,107
16,754,436
17,574,641
21,050,564
19,563,898
20,706,155
19,775,771
15,319,880
15,269,872
17,528,393
16,777,852
19,483,930
21,120,716
20,555,562
18,238,592
18,285,526
17,424,150
16,861,043
16,343,508
14,979,293
14,323,193
16,536,497
20,999,050
17,067,469
18,387,240
18,487,794
18,326,785
19,075,950
24,916,851
23,083,856
61,705,486
62,483,065
53,016,721
55,481,866
51,082,892
57,044,107
52,733,977
53,331,164
28,860,666
18,539,964
17,200,977
17,200,97718,539,96428,860,66653,331,16452,733,97757,044,10751,082,89255,481,86653,016,72162,483,06561,705,48623,083,85624,916,85119,075,95018,326,78518,487,79418,387,24017,067,46920,999,05016,536,49714,323,19314,979,29316,343,50816,861,04317,424,15018,285,52618,238,59220,555,56221,120,71619,483,93016,777,85217,528,39315,269,87215,319,88019,775,77120,706,15519,563,89821,050,56417,574,64116,754,43616,023,10717,997,876
   > Total Current Liabilities 
8,360,165
6,633,067
11,881,570
13,254,133
14,734,679
13,893,609
15,523,691
14,545,214
10,105,973
9,954,647
11,569,759
10,937,080
12,177,147
14,340,577
14,211,136
12,932,577
13,870,034
13,664,592
13,155,005
12,762,483
11,188,844
10,274,098
10,703,838
15,728,769
11,164,741
12,130,984
12,464,609
13,533,265
14,381,236
19,799,926
19,380,220
24,807,938
60,207,600
50,892,155
53,563,693
46,364,634
52,406,703
47,914,002
48,460,789
28,030,185
17,564,910
15,934,350
15,934,35017,564,91028,030,18548,460,78947,914,00252,406,70346,364,63453,563,69350,892,15560,207,60024,807,93819,380,22019,799,92614,381,23613,533,26512,464,60912,130,98411,164,74115,728,76910,703,83810,274,09811,188,84412,762,48313,155,00513,664,59213,870,03412,932,57714,211,13614,340,57712,177,14710,937,08011,569,7599,954,64710,105,97314,545,21415,523,69113,893,60914,734,67913,254,13311,881,5706,633,0678,360,165
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
7,026,602
4,577,112
4,030,680
3,859,440
3,688,200
2,680,530
1,672,860
836,430
6,500
40,000
138,000
164,000
1,006,452
170,700
142,700
165,600
180,500
181,500
229,928
235,128
236,265
243,563
163,185
204,637
673,500
673,500
0
0
0
000673,500673,500204,637163,185243,563236,265235,128229,928181,500180,500165,600142,700170,7001,006,452164,000138,00040,0006,500836,4301,672,8602,680,5303,688,2003,859,4404,030,6804,577,1127,026,6020000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
7,026,602
4,577,112
4,030,680
3,859,440
3,688,200
2,680,530
1,672,860
836,430
6,500
12,500
18,750
0
0
0
0
0
0
0
0
0
0
0
17,531,212
18,122,498
19,232,530
19,904,071
6,120,052
3,081,436
0
03,081,4366,120,05219,904,07119,232,53018,122,49817,531,2120000000000018,75012,5006,500836,4301,672,8602,680,5303,688,2003,859,4404,030,6804,577,1127,026,6020000000000000
       Accounts payable 
2,459,210
1,291,827
2,526,762
3,135,326
3,579,465
3,144,551
4,663,726
4,046,207
3,108,755
4,850,131
5,216,348
4,016,359
3,646,404
5,485,061
5,506,708
4,647,996
4,882,766
5,567,038
5,377,679
5,480,856
4,620,754
0
4,046,017
8,334,950
4,096,961
5,919,559
6,225,426
6,450,326
6,704,014
12,534,121
8,495,259
0
0
0
0
8,603,399
13,644,803
10,280,396
10,822,114
11,428,301
5,402,091
0
05,402,09111,428,30110,822,11410,280,39613,644,8038,603,39900008,495,25912,534,1216,704,0146,450,3266,225,4265,919,5594,096,9618,334,9504,046,01704,620,7545,480,8565,377,6795,567,0384,882,7664,647,9965,506,7085,485,0613,646,4044,016,3595,216,3484,850,1313,108,7554,046,2074,663,7263,144,5513,579,4653,135,3262,526,7621,291,8272,459,210
       Other Current Liabilities 
3,751,894
3,192,179
2,829,732
3,565,933
3,942,685
3,509,213
3,591,643
3,855,744
5,349,727
3,632,211
4,334,479
5,031,770
5,115,949
5,090,494
4,029,953
4,187,545
5,058,532
4,105,808
4,797,529
5,190,769
5,246,550
10,212,158
6,327,776
6,869,753
6,513,183
4,953,579
5,655,678
6,428,381
6,916,946
6,521,518
10,175,143
0
0
0
0
130,001
130,000
130,000
129,999
130,000
209,999
0
0209,999130,000129,999130,000130,000130,001000010,175,1436,521,5186,916,9466,428,3815,655,6784,953,5796,513,1836,869,7536,327,77610,212,1585,246,5505,190,7694,797,5294,105,8085,058,5324,187,5454,029,9535,090,4945,115,9495,031,7704,334,4793,632,2115,349,7273,855,7443,591,6433,509,2133,942,6853,565,9332,829,7323,192,1793,751,894
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
336,158
385,970
514,162
688,510
830,481
975,054
1,266,627
1,266,627975,054830,481688,510514,162385,970336,15800000000000000000000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
96,304
85,671
575,000
568,750
437,502
378,676
304,384
280,544
264,740
15,217,066
120,124
110,908
110,231
184,570
234,383
362,575
392,216
0
0
0
000392,216362,575234,383184,570110,231110,908120,12415,217,066264,740280,544304,384378,676437,502568,750575,00085,67196,3040000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
-7,026,602
-4,577,112
-4,030,680
-3,859,440
-3,688,200
-2,680,530
-1,672,860
-836,430
-6,500
-40,000
-138,000
-164,000
-1,006,452
-170,700
-142,700
-165,600
-180,500
-181,500
-229,928
-235,128
-236,265
-243,563
-7,861
9,660
-171,954
-111,896
495,729
428,717
0
0428,717495,729-111,896-171,9549,660-7,861-243,563-236,265-235,128-229,928-181,500-180,500-165,600-142,700-170,700-1,006,452-164,000-138,000-40,000-6,500-836,430-1,672,860-2,680,530-3,688,200-3,859,440-4,030,680-4,577,112-7,026,6020000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
131,588
131,587
131,588
131,587
131,587
131,586
0
0131,586131,587131,587131,588131,587131,58800000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
2,108,751
2,397,071
2,295,238
2,376,781
2,345,616
2,162,868
2,066,125
2,047,862
1,940,389
1,906,298
1,879,439
1,971,020
1,862,990
1,814,083
1,715,406
1,589,058
1,517,550
1,436,931
0
0
0
0
0
0
0
0
0
0
0
000000000001,436,9311,517,5501,589,0581,715,4061,814,0831,862,9901,971,0201,879,4391,906,2981,940,3892,047,8622,066,1252,162,8682,345,6162,376,7812,295,2382,397,0712,108,7510000000000000
> Total Stockholder Equity
41,376,753
42,046,781
42,263,054
42,675,168
42,369,986
44,186,260
44,729,028
45,302,046
44,336,803
47,145,259
47,415,326
48,604,222
48,772,176
50,900,600
51,180,744
51,494,401
51,272,772
52,422,836
53,301,649
53,716,790
53,430,597
58,424,780
59,202,069
59,708,396
59,827,305
60,642,690
61,958,796
59,919,961
60,830,905
62,291,693
75,470,206
74,860,552
76,350,619
82,404,416
83,791,851
83,785,873
84,521,091
84,523,987
85,077,686
83,062,664
82,791,962
83,577,470
83,577,47082,791,96283,062,66485,077,68684,523,98784,521,09183,785,87383,791,85182,404,41676,350,61974,860,55275,470,20662,291,69360,830,90559,919,96161,958,79660,642,69059,827,30559,708,39659,202,06958,424,78053,430,59753,716,79053,301,64952,422,83651,272,77251,494,40151,180,74450,900,60048,772,17648,604,22247,415,32647,145,25944,336,80345,302,04644,729,02844,186,26042,369,98642,675,16842,263,05442,046,78141,376,753
   Common Stock
2,600,000
2,600,000
2,600,000
2,600,000
2,750,000
2,803,717
2,835,947
2,835,947
2,985,947
2,985,947
2,985,947
2,985,947
3,135,947
3,225,031
3,225,031
3,225,031
3,425,031
3,450,258
3,450,258
3,450,258
3,650,258
3,650,258
3,750,338
3,750,338
4,000,338
4,000,338
4,000,338
4,000,338
4,150,338
4,150,338
4,150,338
4,150,338
4,250,338
4,250,338
4,250,338
4,250,338
4,350,338
4,350,338
4,350,338
0
0
0
0004,350,3384,350,3384,350,3384,250,3384,250,3384,250,3384,250,3384,150,3384,150,3384,150,3384,150,3384,000,3384,000,3384,000,3384,000,3383,750,3383,750,3383,650,2583,650,2583,450,2583,450,2583,450,2583,425,0313,225,0313,225,0313,225,0313,135,9472,985,9472,985,9472,985,9472,985,9472,835,9472,835,9472,803,7172,750,0002,600,0002,600,0002,600,0002,600,000
   Retained Earnings Total Equity000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000000000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17,836,057
17,836,057
17,836,057
17,836,057
17,836,057
17,836,057
17,836,057
17,836,057
18,490,158
17,836,057
17,836,057
17,836,057
17,836,057
17,836,057
17,836,057
17,836,057
17,836,057
0
0
0
00017,836,05717,836,05717,836,05717,836,05717,836,05717,836,05717,836,05717,836,05718,490,15817,836,05717,836,05717,836,05717,836,05717,836,05717,836,05717,836,05717,836,0570000000000000000000000
   Treasury Stock0000000000-3,061,997-3,061,997-3,061,997-2,981,396-2,981,396-2,981,396-2,981,396-2,960,463-2,812,411-2,395,693000-132,350-132,350-97,395-97,395-97,395-97,395-67,921-67,921-67,921-67,921-22,287-22,287-22,287-22,287-7,063-7,063-7,063-7,0630
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
-321,577
-321,577
-321,577
-321,578
0
1
0
0
0
654,101
654,101
654,101
-29,189
0
-3,613,079
-3,522,751
-3,522,752
-3,551,941
654,101
654,101
654,101
654,101
654,101
654,101
654,101
654,101
0
0
0
000654,101654,101654,101654,101654,101654,101654,101654,101-3,551,941-3,522,752-3,522,751-3,613,0790-29,189654,101654,101654,10100010-321,578-321,577-321,577-321,5770000000000000



6.3. Balance Sheets

Currency in KRW. All numbers in thousands.




6.4. Cash Flows

Currency in KRW. All numbers in thousands.




6.5. Income Statements

Currency in KRW. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in KRW. All numbers in thousands.

Gross Profit (+$)
totalRevenue89,569,472
Cost of Revenue-69,648,587
Gross Profit19,920,88519,920,885
 
Operating Income (+$)
Gross Profit19,920,885
Operating Expense-87,074,964
Operating Income2,494,508-67,154,079
 
Operating Expense (+$)
Research Development785,234
Selling General Administrative4,079,216
Selling And Marketing Expenses0
Operating Expense87,074,9644,864,450
 
Net Interest Income (+$)
Interest Income2,051,355
Interest Expense-2,482,463
Other Finance Cost-2,211,374
Net Interest Income-2,642,482
 
Pretax Income (+$)
Operating Income2,494,508
Net Interest Income-2,642,482
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-1,928,7752,494,508
EBIT - interestExpense = -2,482,463
-117,546
2,364,917
Interest Expense2,482,463
Earnings Before Interest and Taxes (EBIT)0553,688
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-1,928,775
Tax Provision-394,291
Net Income From Continuing Ops-2,323,066-2,323,066
Net Income-117,546
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net02,642,482
 

Technical Analysis of Seoulin
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Seoulin. The general trend of Seoulin is BEARISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Seoulin's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-14.3%) Bearish trend (14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Seoulin Bioscience Co.Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 10,390 < 10,843 < 10,892.

The bearish price targets are: 6,180 > 6,130.

Tweet this
Seoulin Bioscience Co.Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Seoulin Bioscience Co.Ltd. The current mas is .

The long score for the Moving Averages is 6/14.
The longshort score for the Moving Averages is -2/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Seoulin Bioscience Co.Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Seoulin Bioscience Co.Ltd. The current macd is 391.74.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Seoulin price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Seoulin. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Seoulin price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Seoulin Bioscience Co.Ltd Daily Moving Average Convergence/Divergence (MACD) ChartSeoulin Bioscience Co.Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Seoulin Bioscience Co.Ltd. The current adx is 41.62.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Seoulin shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Seoulin Bioscience Co.Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Seoulin Bioscience Co.Ltd. The current sar is 10,390.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Seoulin Bioscience Co.Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Seoulin Bioscience Co.Ltd. The current rsi is 52.38. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending down: The RSI is trending down. -1
Seoulin Bioscience Co.Ltd Daily Relative Strength Index (RSI) ChartSeoulin Bioscience Co.Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Seoulin Bioscience Co.Ltd. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Seoulin price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Seoulin Bioscience Co.Ltd Daily Stochastic Oscillator ChartSeoulin Bioscience Co.Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Seoulin Bioscience Co.Ltd. The current cci is 19.09.

Seoulin Bioscience Co.Ltd Daily Commodity Channel Index (CCI) ChartSeoulin Bioscience Co.Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Seoulin Bioscience Co.Ltd. The current cmo is 0.93931059.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Seoulin Bioscience Co.Ltd Daily Chande Momentum Oscillator (CMO) ChartSeoulin Bioscience Co.Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Seoulin Bioscience Co.Ltd. The current willr is -61.75771971.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Seoulin is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Seoulin Bioscience Co.Ltd Daily Williams %R ChartSeoulin Bioscience Co.Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Seoulin Bioscience Co.Ltd.

Seoulin Bioscience Co.Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Seoulin Bioscience Co.Ltd. The current atr is 773.34.

Seoulin Bioscience Co.Ltd Daily Average True Range (ATR) ChartSeoulin Bioscience Co.Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Seoulin Bioscience Co.Ltd. The current obv is 25,227,071.

Seoulin Bioscience Co.Ltd Daily On-Balance Volume (OBV) ChartSeoulin Bioscience Co.Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Seoulin Bioscience Co.Ltd. The current mfi is 83.49.

The long score for the Money Flow Index (MFI) is 2/2.
The longshort score for the Money Flow Index (MFI) is 2/(-2 +2).

  • MFI > 50: +1
  • MFI > 80: +1
Seoulin Bioscience Co.Ltd Daily Money Flow Index (MFI) ChartSeoulin Bioscience Co.Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Seoulin Bioscience Co.Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-01CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-06RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-07ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-08-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-14STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-08-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-19BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-08-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-08-21ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-08-27WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-09-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-09-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-09-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-10-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-15STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-10-17CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-10-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-29WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-31STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-01STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-11STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-13ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-19RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-29STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-12-02WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-12-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-12-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-12-10ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-16STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside

6.3. Candlestick Patterns

Seoulin Bioscience Co.Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Seoulin Bioscience Co.Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.379
Ma 20Greater thanMa 507,379.500
Ma 50Greater thanMa 1007,187.800
Ma 100Greater thanMa 2007,609.000
OpenGreater thanClose7,640.000
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Seoulin with someone you think should read this too:
  • Are you bullish or bearish on Seoulin? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Seoulin? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Seoulin Bioscience Co.Ltd

I send you an email if I find something interesting about Seoulin Bioscience Co.Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Seoulin Bioscience Co.Ltd.

Receive notifications about Seoulin Bioscience Co.Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.